Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10448292" target="_blank" >RIV/00064203:_____/22:10448292 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/22:10448292

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=XjgOAGHHV_" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=XjgOAGHHV_</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijid.2022.09.013" target="_blank" >10.1016/j.ijid.2022.09.013</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?

Popis výsledku v původním jazyce

Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an emphasis on rapid restoration of the gut microbiota to minimise the risk of infection relapses. Oral administration of metronidazole results in low concentration in stool and interaction with faecal microbiota reduces its antimicrobial bioactivity. Reported elevated minimum inhibitory concentrations of metronidazole in epidemic C. difficile ribotypes and the emergence of plasmid-mediated resistance to metronidazole represent additional potential risks for clinical failure. If metronidazole is the only CDI treatment option, antimicrobial susceptibility testing on agar containing haem should be performed in C. difficile isolate. Compared to metronidazole, oral vancomycin and fidaxomicin reach very high concentrations in the stool, and therefore, have the ability to quickly reduce C. difficile shedding. Healthcare facilities with higher CDI incidence and/or occurrence of epidemic ribotypes should not use metronidazole because prolonged C. difficile shedding can increase the risk for further C. difficile transmission. Only fidaxomicin has a narrow spectrum of antimicrobial activity, which might be together with persistence on spores the main contributing factors to reducing of recurrent CDI rates.

Název v anglickém jazyce

Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?

Popis výsledku anglicky

Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an emphasis on rapid restoration of the gut microbiota to minimise the risk of infection relapses. Oral administration of metronidazole results in low concentration in stool and interaction with faecal microbiota reduces its antimicrobial bioactivity. Reported elevated minimum inhibitory concentrations of metronidazole in epidemic C. difficile ribotypes and the emergence of plasmid-mediated resistance to metronidazole represent additional potential risks for clinical failure. If metronidazole is the only CDI treatment option, antimicrobial susceptibility testing on agar containing haem should be performed in C. difficile isolate. Compared to metronidazole, oral vancomycin and fidaxomicin reach very high concentrations in the stool, and therefore, have the ability to quickly reduce C. difficile shedding. Healthcare facilities with higher CDI incidence and/or occurrence of epidemic ribotypes should not use metronidazole because prolonged C. difficile shedding can increase the risk for further C. difficile transmission. Only fidaxomicin has a narrow spectrum of antimicrobial activity, which might be together with persistence on spores the main contributing factors to reducing of recurrent CDI rates.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

<a href="/cs/project/LX22NPO5103" target="_blank" >LX22NPO5103: Národní institut virologie a bakteriologie</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Infectious Diseases

ISSN

1201-9712

e-ISSN

1878-3511

Svazek periodika

124

Číslo periodika v rámci svazku

November

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

118-123

Kód UT WoS článku

000875838200004

EID výsledku v databázi Scopus

2-s2.0-85139738324